“Anti corruption” hit hard.
On the evening of January 25, Hybio Pharmaceutical Co.Ltd(300199) announced that it was learned from the public security and judicial organs that the former president and the former Secretary of the company were both taken compulsory measures and were suspected of job occupation.
Affected by the news, the share price of Hybio Pharmaceutical Co.Ltd(300199) fell by more than 9% in the morning. As of noon, Hybio Pharmaceutical Co.Ltd(300199) fell 8.57% to 12.37 yuan / share, with a market value of 11.3 billion.
In addition to Hybio Pharmaceutical Co.Ltd(300199) , recently, listed companies have made continuous anti-corruption actions. Tencent, Byd Company Limited(002594) and other well-known listed companies have recently attacked internal corruption.
suspected of job-related crime, former director of the company,
The president of has been arrested and more than 36 million have been recovered
On the evening of January 25, Hybio Pharmaceutical Co.Ltd(300199) (300199, SZ) announced that it was learned from the public security and judicial organs that Yuan Jiancheng, the former director and President of the company, had been approved for arrest on suspicion of job-related crimes, and Zhu Wenfeng, the former director, Secretary of the board of directors and vice president, had been criminally detained on suspicion of job occupation. The matters involved were related to his tenure in the listed company.
Hybio Pharmaceutical Co.Ltd(300199) pointed out that the above cases were found by the company’s internal self-examination and reported to the public security organ. At present, the case is still under investigation by the public security and judicial organ. More than 36 million yuan has been recovered from the job-related crime funds involved in the former director and President yuan Jiancheng. The company will continue to pay attention to the progress of the above matters and fulfill the obligation of information disclosure in time in strict accordance with the provisions and requirements of relevant laws and regulations. At the same time, the company has strengthened the construction of internal control, further improved the level of governance, established and improved the prevention mechanism, investigation mechanism and accountability system, and resolutely cracked down on illegal acts detrimental to the interests of listed companies, “Zero tolerance” for corruption and return all investors with practical actions.
Hybio Pharmaceutical Co.Ltd(300199) focusing on the polypeptide pharmaceutical industry chain in the subdivided field of the pharmaceutical industry, it is a national high-tech enterprise specializing in the R & D, production and sales of polypeptide drugs. It was IPO on the Shenzhen Stock Exchange in 2011. The company has great influence in the global polypeptide pharmaceutical industry, and the actual controller is the “three brothers” of Zeng shaogui family.
In addition to Hybio Pharmaceutical Co.Ltd(300199) , recently, listed companies have made continuous anti-corruption actions. Tencent, Byd Company Limited(002594) and other well-known listed companies have recently attacked internal corruption. In January 25th, Tencent group disclosed the anti fraud situation in last year’s official account on WeChat public’s “sunshine Tencent”. In 2021, the anti fraud investigation department of Tencent found and dealt with more than 50 cases of violating the “Tencent high voltage line”, nearly 70 people were dismissed for violating the “Tencent high voltage line”, more than 10 people were transferred to the public security organ for handling due to suspected crimes, and a list of 13 companies that will never cooperate was added. In January 24th, the “clean Byd Company Limited(002594) ” WeChat official account issued a letter to Byd Company Limited(002594) partner. In the letter, Byd Company Limited(002594) said that in 2021, a total of 28 suppliers were investigated by Byd Company Limited(002594) for breach of integrity cooperation agreements. In addition, in 2021, Byd Company Limited(002594) investigated and dealt with 94 employees who were dishonest and seriously violated regulations (dismissed and entered into the delisting query system); Seven cases involving 22 persons were transferred to the public security organ for investigation, and criminal responsibility was investigated according to law.
last year’s profit loss of 400 million
The share price of has risen nearly 90%
On the evening of January 24, Hybio Pharmaceutical Co.Ltd(300199) released the performance forecast for 2021. It is expected to make a profit of 25 million yuan to 37.5 million yuan in 2021, deducting a non net profit loss of 380 million yuan to 430 million yuan. It is estimated that during the reporting period, the net profit attributable to the parent company will turn from loss to profit compared with the previous year.
Hybio Pharmaceutical Co.Ltd(300199) said in the announcement that due to the adjustment of the company’s investment positioning of Shanghai General Healthy Information And Technology Co.Ltd(605186) (hereinafter referred to as ” Shanghai General Healthy Information And Technology Co.Ltd(605186) “) in 2021, the equity accounting method of Shanghai General Healthy Information And Technology Co.Ltd(605186) was changed from equity method to fair value measurement, resulting in a significant increase in investment income over the same period of last year.
It is worth mentioning that Hybio Pharmaceutical Co.Ltd(300199) had a “big face change” in the previous performance forecast. When the performance forecast for 2020 is released, Hybio Pharmaceutical Co.Ltd(300199) it is expected that the net profit attributable to the parent company in 2020 will be 20-30 million yuan, and the non net profit deducted is expected to be 180-240 million yuan. After that, Hybio Pharmaceutical Co.Ltd(300199) revised the notice. After the correction, the expected loss of net profit attributable to the parent company is 550 million yuan – 650 million yuan, and the expected loss of deducting non net profit is 560 million yuan – 660 million yuan.
At the close on January 25, Hybio Pharmaceutical Co.Ltd(300199) closed at 13.53 yuan, down 17.95%, with the latest market value of 12.4 billion yuan. Last year, the stock price of Hybio Pharmaceutical Co.Ltd(300199) rose nearly 90%.
was named by the securities regulatory bureau
It is worth noting that in early January last year, Hybio Pharmaceutical Co.Ltd(300199) received the decision on administrative supervision measures issued by Shenzhen Securities Regulatory Bureau due to untimely information disclosure and problems in internal control and financial accounting.
According to the decision, Shenzhen Securities Regulatory Bureau conducted an on-site inspection on Hybio Pharmaceutical Co.Ltd(300199) in August 2020. The inspection found that the operation of the board of directors and the general meeting of shareholders was not standardized, the information disclosure was not timely, and there were problems in internal control and financial accounting. The company decided to take administrative supervision measures to order Hybio Pharmaceutical Co.Ltd(300199) to correct, and required the listed company to submit a written rectification report within 30 days from the date of receiving the decision.
Among them, the Shenzhen Securities Regulatory Bureau found in the inspection that the listed companies had defects in return control, resulting in inaccurate financial accounting, including irregular revenue recognition and inaccurate provision for inventory falling price reserves; Meanwhile, the listed company terminated some R & D projects in 2019 and there were signs of impairment, but the company did not conduct impairment test on the above assets in the 2019 financial report. At the same time, there are also problems that the construction in progress is not transferred to shareholders’ assets in time and the internal control related to the sales cycle is not perfect.
In addition, Hybio Pharmaceutical Co.Ltd(300199) also has violations related to untimely information disclosure. For example, the disclosure of stock pledge information of major shareholders was not timely. From 2017 to 2019, the company did not disclose relevant information within 2 days after the occurrence of stock pledge of controlling shareholders for many times, but concentrated multiple pledges occurred at different times in one announcement for unified disclosure, etc.
